Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04653792
Other study ID # preg2020micro
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date June 4, 2018
Est. completion date April 17, 2020

Study information

Verified date December 2020
Source Ziauddin University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the effect of pregabalin in reducing the neuropathic pain in postoperative patients who have undergone single level Microdiscectomy for prolapsed intervetebral lumbar disc.


Description:

All patients were informed in detailed regarding the risk and complications and given written and informed consent, coming to our clinics were assessed by one of the senior team members of the spine, patient fulfilling the eligibility criteria were selected and included in the study. One week before the surgery the patients who met the eligibility criteria were randomized in a double-blind manner (participant and investigator) in a ratio of 1:1 into Group-A (Pregabalin 7mg, twice daily) or Group-B (Placebo, twice daily). The pain scores were recorded by VAS and Roland Morris score system on preoperative day compared to the scores on the 1st week postoperative follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 84
Est. completion date April 17, 2020
Est. primary completion date April 17, 2020
Accepts healthy volunteers No
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: - All patients with severe CLBP and/or leg pain - Patients with static or dynamic leg pain - Patients with leg pain resulting from localized lumbar or lumbosacral segmental instability - Spinal stenosis at levels L2-S1 or caused by isthmic spondylolisthesis (grade I and II) Exclusion Criteria: - Patients with previous lumbar surgery - Patients allergic to gabapentinoids - Patients with renal impairments - Patients who are already on opioids, benzodiazepines, barbiturates, ethanol (alcohol) - Patient presented with diabetes and other drugs that depress the central nervous system - Patients who are already on ACE inhibitors as they may enhance the adverse/toxic effect of Pregabalin.

Study Design


Intervention

Drug:
Pregabalin 75mg
75 mg capsule
Device:
Placebo
75 mg

Locations

Country Name City State
Pakistan Dr. Ziauddin University Hospital Clifton Campus Karachi Sindh

Sponsors (1)

Lead Sponsor Collaborator
Ziauddin University

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary change from preoperative pain score using a 10 point visual analog scale (VAS pain scale) at 1 week post surgery for PID VAS pain scale is a validated, self-reported instrument assessing average pain intensity over the past 24 hours period. Possible scores being 0 (no pain) and 10 (worst possible pain). Change = (1 week post surgery - preoperative pain) Preoperative and one week postoperative
See also
  Status Clinical Trial Phase
Withdrawn NCT06460194 - Treatment of Frostbite Sequelae With Botulinum Toxin A Phase 2
Recruiting NCT05009394 - Surgical Treatments for Postamputation Pain N/A
Not yet recruiting NCT06185816 - Non-Invasive Pulsed Radiofrequency for the Treatment of Neuropathic Pain Phase 2/Phase 3
Enrolling by invitation NCT03494842 - TENS for Suction Evacuation for Termination of 1st Trimester Pregnancies N/A